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Patients with head and neck squamous cell carcinoma (HNSCC) are at considerable risk for death, with 5-year relative
survival rates of approximately 60%. The profound multifaceted deﬁciencies in cell-mediated immunity that persist in most
patients after treatment may be related to the high rates of treatment failure and second primary malignancies. Radiotherapy
and chemoradiotherapy commonly have severe acute and long-term side eﬀects on immune responses. The development of
immunotherapies reﬂects growing awareness that certain immune system deﬁciencies speciﬁc to HNSCC and some other cancers
maycontributetothepoorlong-termoutcomes.Systemiccell-mediatedimmunotherapyisintendedtoactivatetheentireimmune
system and mount a systemic and/or locoregional antitumor response. The delivery of cytokines, either by single cytokines, for
example, interleukin-2, interleukin-12, interferon-γ, interferon-α, or by a biologic mix of multiple cytokines, such as IRX-2,
may result in tumor rejection and durable immune responses. Targeted immunotherapy makes use of monoclonal antibodies
or vaccines. All immunotherapies for HNSCC except cetuximab remain investigational, but a number of agents whose eﬃcacy and
tolerability are promising have entered phase 2 or phase 3 development.
Copyright © 2009 A. D. Rapidis and G. T. Wolf.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Head and neck cancer is a prevalent condition in the United
States and the eighth leading site of new cancer cases among
men. It is estimated that 35,310 new cancers of the oral
cavity and pharynx will have been diagnosed in 2008 in
the United States, and that 7,590 Americans will have died
due to such cancers [1]. More than 80% of head and neck
cancers (excluding cancers of the thyroid, salivary glands,
and nasopharynx; and nonmelanoma skin cancer) are head
and neck squamous cell carcinomas (HNSCCs) [2].
Death rates from cancers of the oral cavity and pharynx
declined from 1979 to 2000 in the United States, but they
have since then remained stable. The overall 5-year relative
survival rate at diagnosis is 59.1%, with a range from 81.8%
for early disease at diagnosis to 26.5% for advanced disease.
For diagnoses at all stages combined, the 10-year relative
survival rate for cancers of the oral cavity and pharynx is
48%. For cancer of the larynx, the 5-year relative survival
rate at all stages of diagnosis is 62.9%, ranging from 81.1%
for early cancers to a dismal 23.9% for cancers with distant
metastases at the time of diagnosis [1].
Mortality in head and neck cancers in the United States
is higher in blacks than in whites: for cancer of the larynx,
the 5-year survival rate in 2000 was 67% for whites and 40%
for blacks; for cancer of oral cavity and pharynx, the rate was
65% for whites and 46% for blacks [3].
In light of these discouraging data, the development of
novel therapies for HNSCC has become a priority. One
of the most exciting research avenues is immunotherapy,
thanks to advances in the understanding of the relationships
between tumors and the host immune system, as well as to
developments in the technology for identifying molecular
therapeutic targets. This article reviews the rationale for2 Journal of Oncology
immunotherapy in HNSCC and the principal approaches
under investigation.
2. Etiology, Diagnosis,andStagingof HNSCC
The development and progression of HNSCC are considered
to result from stepwise alterations of cellular, genetic,
biochemical, and molecular pathways at multiple epithelial
sites within the aerodigestive tract [4]. This progression
probably explains, in part, the high incidence of second
primary tumors, the tendency for patients to present with
premalignant lesions at multiple sites in the aerodigestive
tract, and the high rate of progression of these premalignan-
cies [5].
Tumor carcinogenesis in HNSCC involves dynamic
interactions among many factors. Exposure of the upper
aerodigestive tract to alcohol or tobacco is one of the
chief risk factors for many HNSCCs, and exposure to both
increases the risk beyond what would be expected if the
agents simply had additive eﬀects [2]. Another common
risk factor is alteration of the function of the p53 tumor
suppressor gene, which may be caused by either gene
mutation or infection with an oncogenic type of human
papillomavirus (HPV) [6, 7]. In some patients, particularly
those with oropharyngeal cancer not associated with p53
mutation or the molecular impacts of alcohol and tobacco,
HPV infection can cause head and neck cancer even in the
absence of other molecular alterations [4, 8]. All of these risk
factors are likely to result from and contribute to suppression
of the patient’s immune system, as is the tumor itself [9].
Diagnosis of HNSCC is based on a history and physical
examination and computed tomography and/or magnetic
resonance imaging as needed, chest imaging, pathology
review, and biopsy [10]. In advanced HNSCC, positron
emission tomography is an increasingly useful new modality
for assessing lymph node involvement, distant metastases,
and synchronous second primary tumors [11].
RelativelysmallprimaryHNSCCswithnonodalinvolve-
ment are usually classiﬁed as stage I or II, and large primary
tumors that may have invaded nearby structures or spread
to regional lymph nodes are classiﬁed as stage III or IV [10].
Generally,stageIorIIdiseaseisdiscussedas“earlystage”and
stage III or IV disease is termed “advanced stage” [12].
3. Current Therapeutic Options
Approximately 40% of patients with HNSCC present with
early-stagedisease,andeithersurgicalresectionorradiother-
apy is recommended as a single treatment modality [10].
Most patients (60%) present with locally advanced disease
[10] and require a multidisciplinary approach using some
combination of surgery, radiotherapy, and chemotherapy
[4, 13].
Inadditiontoconsideringthestageofcancer,oncologists
must equally consider the site of disease. Lesions in the
oral cavity are often treated with surgery followed by
radiotherapy or chemoradiotherapy (CRT). Tumors located
intheoropharynx,hypopharynx,nasopharynx,orlarynxare
usually treated with CRT ﬁrs [14].
As it is in many other kinds of cancer, immunotherapy is
emerging as an important new option in treating HNSCC.
The monoclonal antibody (MAb) cetuximab, which binds
to the EGF receptor, is approved by the US Food and Drug
Administration as ﬁrst-line treatment of locally or regionally
advanced HNSCC in combination with radiotherapy. As a
single agent, cetuximab is indicated for the treatment of
patients with recurrent or metastatic HNSCC for whom
prior platinum-based therapy has failed [15]. Although tech-
nically considered a molecular targeted agent that inhibits
the EGFR, cetuximab is a chimeric MAb. Its administration
is often associated with a generalized allergic skin rash that
correlatesdirectlywithtumorresponses.Whetherthebeneﬁt
of adding this agent is due to EGFR inhibition and down-
streammoleculareﬀectsonpathwaysofcellproliferationand
apoptosis or due to antibody-mediated immune responses is
unclear. It is less likely due to a direct allergic response since
nonneutralizing antibodies to cetuximab are only detected
in 5% of treated patients. Recent evidence has shown that
MAbs mediate antibody-dependent cellular cytotoxicity, and
induce activation of cellular immunity, including natural
killer and T cells [16]. Other immunotherapies being
explored for treatment of HNSCC are discussed later in this
paper.
In recent years, there have been many improvements
in the modalities used to treat HNSCC. Minimally inva-
sive surgical techniques followed by improved reconstruc-
tion procedures frequently result in better functional and
esthetic outcomes. Improved microvascular reconstruc-
tions have enhanced functional results of major tumor
resections. Intensity modulation in the use of radiation
therapy may be reducing toxicity, and altered fraction-
ation schedules may be improving local disease con-
trol and late toxicity [4]. Multidrug chemotherapy reg-
imens incorporating the newest agents and molecular
targeted therapies have shown some eﬃcacy and tolera-
ble toxicity in both recurrent and previously untreated
patients.
In addition to eﬃcacy considerations, impact on quality
of life remains a major consideration in selecting appropriate
treatment for HNSCC. The tumors themselves commonly
jeopardize physiologic functions, such as the patient’s ability
to chew, breath, and swallow; the senses of taste, smell,
and/or hearing; as well as personal characteristics such
as voice and appearance [10]. Common side eﬀects of
radiotherapy include ﬁbrosis of normal tissue, scarring,
and long-term dry mouth or dysphagia [17]. CRT involves
the substantial risks for severe acute and long-term side
eﬀects associated with both chemotherapy and radiotherapy,
including mucositis, dermatitis, pain, dysphagia, dry mouth,
local, or systemic infections, dental problems, depression,
speech diﬃculties, and occasionally breathing diﬃculties, as
well as immune suppression [14]. Combination with altered
fractionation or intensiﬁed radiation increases the burden.
Cisplatin,thepreferredchemotherapeuticagentinCRT[10],
is severely toxic when used in combination with other drugs
and radiation, and patients unable to tolerate cisplatin have
an especially high cumulative risk of death: 20% to 25% at 2
years [14].Journal of Oncology 3
4. Novel Therapeutic Directions:
Engagingthe ImmuneSystemand
Antitumor Immunity
The HNSCC patient’s immune system is an important
elementinthedevelopmentofthediseaseand,inmanycases,
in the response to treatment. The microenvironment in
which HNSCC arises is populated with numerous immune
cells and soluble factors produced by these cells. Both
cutaneous skin and aerodigestive tract mucosa are highly
immunoreactive organs. In this environment, it is likely
that many newly appearing tumor cells will be rapidly
eliminated, leaving those which survive particularly resistant
to the body’s innate and adaptive immune mechanisms
[18].
As with other cancers, there are numerous methods
by which HNSCC may avoid recognition and destruction
by the immune system. One strategy is to escape immune
system recognition via downregulation of human leukocyte
antigens (HLAs), which are necessary to present antigens
on malignant cells to T cells [19, 20], or via apoptosis of
circulating T cells, which seems to be mediated at least in
part by tumor-derived Fas ligand [21]. Another potential
mechanism is secretion of immunosuppressive factors such
as prostaglandin E2 [22], vascular endothelial growth factor
(VEGF) [23], interleukin (IL)-10, or transforming growth
factor-β [24]. Additionally, immune defenses can be directly
inhibited by “suppressor T cells,” now known as regulatory
Tc e l l s( T reg)[ 9]. Immune reactivity is not simply turned
on or oﬀ, rather, HNSCC and certain other cancers avoid
the immune response by modulating responses that are
more eﬀective against tumors, for example, TH1 responses,
and enhancing those which are less eﬀective, for example,
TH2 responses. TH1 responses are classically deﬁned by the
production of interferon (IFN)-α, granulocyte macrophage
colony-stimulating factor (GM-CSF), and IL-2, whereas TH2
responsesaredeﬁnedbyexpressionofcytokinessuchasIL-4,
IL-6, and IL-10 [24].
In most types of cancer, these processes are thought
to take place concurrently [24]. Some immune system
deﬁciencies, however, are speciﬁc to HNSCC and a few other
cancers [25], and they are thought to contribute to the poor
long-term survival rate in HNSCC. Patients with HNSCC
have been shown to have lymph nodes that are reduced
in size and have diminished T-cell content. Reduced T-cell
function has been linked to shorter disease-speciﬁc survival
[26]. Defects in dendritic cell (DC) function are also
a hallmark of immune system dysfunction in HNSCC
[27]. For example, the accumulation of histiocytes/DCs in
the distended sinuses of lymph nodes, known as sinus
histiocytosis, is a reﬂection of DC defects, and is present
in the lymph nodes of HSNCC patients. The buildup
of these cells in the nodal sinuses prevents their entry
into the node parenchyma, and maturation is, therefore,
impaired, preventing optimal T-cell stimulation [28]. Low
inﬁltration of DCs in tumor environments (linked to
abnormalities in the TcR-associated zeta chain in TILs)
was correlated with poor prognosis for disease survival
[29].
Speciﬁc defects in cell-mediated immunity may also
include progressive decreases in dermal delayed-type hyper-
sensitivity responses, T-cell counts in blood, proliferative
responsesofbloodTcellstomitogensorantigenstimulation,
and blood monocyte functions such as chemotaxis and
cytotoxicity [25]. One example is the production by HNSCC
and some other cancers of chemoattractive factors (e.g.,
VEGF) to attract immunosuppressive CD34(+) progenitor
cells that inhibit the capacity of intratumoral lymphoid cells
to become activated [23, 30]. Intriguingly, cell-mediated
immunity may decline even before the tumor develops,
whereas levels of B cells in blood, immunoglobulin, and
complement are usually normal. Therefore, alterations in
humoral immunity seem modest in HNSCC patients [25].
These ﬁndings reﬂect the fact that HNSCC is intrinsically
characterized by deﬁcits in the cellular immune system.
These cancers arise within the oral, nasal, or laryngeal
mucosa, and interact with the local, regional, and systemic
immune cells likely to aﬀect the initiation and promotion of
tumors in these environments [18].
5. Immunotherapy: FutureDirections for
HNSCC Treatment
Immunotherapy is an attractive option for cancer treatment
because both humoral immunity and cell-mediated immu-
nityinvolvecellswithavarietyofclonallydistributedantigen
receptors that can distinguish normal cells from cancerous
cells.Anotheradvantageisthattheimmunesystemcanadapt
to the evolution of cancer cells and can respond in a systemic
fashion [31] .S i g n so fa ni m m u n er e s p o n s eh a v eb e e ns h o w n
to correlate with positive outcomes for cancer patients.
For example, the presence of tumor-inﬁltrating T cells has
been correlated with progression-free survival and/or overall
survival in various cancers, including advanced ovarian
cancer [32], advanced melanoma [33] ,a n dh e a da n dn e c k
cancer [34]. Because the immunobiology of HNSCC is so
intimately associated with the host immune system, the
reversal of immunosuppression is a particularly attractive
therapeutic goal in this tumor type [18]. The remainder of
this article describes immunotherapies now in development
for treatment of HNSCC.
5.1. Systemic Cell-Mediated Immunotherapy in HNSCC. Sys-
temic cell-mediated immunotherapies are nonspeciﬁc, and
attempt to replace the entire immune system by mounting
either a systemic and/or locoregional antitumor response.
For example, adoptive transfer therapy is a form of passive
therapy that entails ex vivo expansion and modiﬁcation of
the patient’s own immune cells, followed by their reinfusion.
The initial use of this approach was based on evidence from
murinestudiesinwhichregressionofestablishedtumorswas
demonstrated[18].Anexampleofitsclinicalapplicationwas
shown in patients with stage IV nasopharyngeal carcinoma,
which expresses Epstein Barr virus (EBV) antigens. EBV-
speciﬁc autologous T cells were reactivated and expanded
exogenously from peripheral blood lymphocytes by stimu-
lating them with EBV-transformed autologous B cells. Aside
from mild inﬂammatory reactions in 2 patients, treatment4 Journal of Oncology
was well tolerated, and 6 of 10 patients demonstrated control
of disease progression [35]. Other groups have reported the
feasibility of generating tumor-reactive T cells and the low
toxicity of this approach in advanced HNSCC [36, 37].
In transfected dendritic cell therapy, autologous den-
dritic cells are transfected with patient tumor DNA, then
reinfused. A proof-of-concept study in HNSCC showed
that this approach yielded eﬀective antigen-presenting cells,
without signs of tumor-induced suppression of dendritic
cells [38]. Another novel approach is the use of intratumoral
dendritic cells in combination with immunosuppressive
chemoradiation. Augmentation of immune responses, long-
term tumor regressions, and increased apoptosis associated
with decreases in intratumoral regulatory T cells have
recently been shown in an animal model of head and neck
cancer [39].
Cytokine-based immunotherapy works by delivering
proinﬂammatory cytokines either locoregionally and/or sys-
temically to elicit an antitumor response. A number of
cytokines are being explored for treatment of HNSCC,
including GM-CSF, IL-2, IFN-γ,I L - 1 2 ,a n da ni n v e s t i g a -
tional multicytokine biologic known as IRX-2. Table 1 lists
the approaches to systemic cell-mediated immunotherapy
for HNSCC that are currently in clinical trials [40], of which
some are discussed in more detail in what follows.
OncoVEXGM-CSF. OncoVEXGM-CSF is a second-generation
oncolytic herpes simplex virus that delivers GM-CSF. In
a phase 1 trial, multiple doses of OncoVEXGM-CSF were
safe and well tolerated in patients with a range of solid
tumortypes,GM-CSFwasexpressed,andtherewasevidence
of antitumor activity [41]. According to preliminary data
from a phase 1/2 study speciﬁc to node-positive advanced
head and neck cancer, the combination of CRT and
OncoVEXGM-CSF produced pathologic complete response in
6 of 8 patients, and non-CRT-related toxicities were mild
[42].
Interleukin-2. T h em a i nf u n c t i o no fI L - 2 ,o n eo ft h e
major proinﬂammatory cytokines produced by T cells, is
to enhance the growth and cytotoxic response of acti-
vated T cells [43]. Multiple studies have shown that IL-2
enhances cellular immune responses to tumors by stimu-
lating the proliferation and activation of several types of
leukocytes with antitumor activity, including natural killer
cells, lymphokine-activated killer cells, antigen-speciﬁc T-
helper cells, cytotoxic lymphocytes, macrophages, and B
cells [44]. The nonspeciﬁc immune reaction ﬁrst causes
tumor shrinkage, followed by tumor-speciﬁc, delayed-type
hypersensitivity, and long-lasting immune memory [45].
Complete or partial responses have been reported after IL-
2 or IL-2-based immunotherapy in head and neck cancer
patients[43].IL-2hasbeenadministeredtoHNSCCpatients
using a variety of delivery methods, including intralesional
injection (recombinant IL-2) and synthetic gene delivery
systems.InadditiontothebeneﬁtsofIL-2itself,theattributes
of some delivery methods may have immunologically ben-
eﬁcial eﬀects, whereas other methods, such as viral-based
vectors, can increase toxicity. In a murine model,giving IL-
2 in a plasmid/cationic lipid formulation resulted not only
in expression of the IL-2 transgene but also in induction of
endogenous IFN-γ and IL-12 [44].Several novel methods of
administering IL-2 have been investigated, including direct
administration of low-dose recombinant IL-2 around the
chin and neck lymph nodes in HNSCC patients [45].
Interferon-γ. Interferon-γ has not been well studied in
HNSCC, but systemic administration of the recombinant
form in a phase 1/2 study in 8 patients produced clinically
measurableimmunologicresponsesin4of9HNSCCtumors
evaluated, resulting in clinically measurable response in 3
patientsandstablediseasein4(1patientprogressed).During
22 days of treatment, a carcinoma in situ in the piriform
sinus disappeared, and the other 3 tumors were reduced in
bulk by 40%, 40%, and 18% [46].
Interferon-α. Interferon-α has been added to other drugs
in the treatment of HNSCC. The combination of IFN-α,
cisplatin, and 5-ﬂuorouracil was associated with an overall
response rate of 55% in patients with advanced esophageal
cancer, accompanied by considerable toxicity [47]. In a
phase 2 study of interferon-α plus isotretinoin and vitamin
E in patients with locally advanced HNSCC, the 5-year
progression-free survival rate was 80% and the 5-year overall
survival rate was 81.3% [48]. Combination treatment with
low dose recombinant IL-2 and interferon alpha-2a has also
produced signiﬁcant clinical tumor regressions in 2 of 11
(18%)heavilypretreatedpatientswithrecurrentdisease[49].
Interleukin-12. Interleukin-12 has eﬀects on both the innate
and adaptive immune systems. It is important in inducing
cellular immunity because it fuels the production and
activation of cytolytic T cells and natural killer cells and
induces the production of cytokines. In a study of 30 patients
with previously untreated HNSCC, injection of recombinant
IL-12 into the primary tumor was shown to increase the
number of natural killer cells and alter the distribution of
B cells in the lymph nodes of the 10 treated patients. These
eﬀects included redistribution of lymphocytes from the
peripheralbloodtothelymphnodesintheneck;asigniﬁcant
increase in natural killer cells and a lower percentage of
THcells in the lymph nodes and the primary tumor; and
a 128-fold increase in IFN-γ mRNA in the lymph nodes.
Finally, the TH2 proﬁle in the lymph nodes of IL-12-treated
patients switched to a TH1p r o ﬁ l e[ 50].
IRX-2. IRX-2 is a promising systemic cell-based strategy
for HNSCC immunotherapy that employs a multifaceted
approach to stimulating immune response. A primary cell-
derived biologic IRX-2 contains multiple cytokines: IL-1, -
2, -6, and -8, tumor necrosis factor-α,I F N - γ,G - C S F ,a n d
GM-CSF.It is sterile, endotoxin-free, and serum-free, and is
produced from puriﬁed human mononuclear cells that are
stimulated by phytohemagglutinin (PHA) under GMP con-
ditions[51].Additionally,intheregimen,cyclophosphamide
is used to inhibit suppressor T-cell function, indomethacin isJournal of Oncology 5
Table 1: Systemic cell-mediated immunotherapies in clinical development in head and neck cancer [40].
Agent Phase Status Study Type Description
IFN-α
2 (NCT00004897)
Active, not
recruiting
(N ∼ 15–45)
Open-label trial
Patients with stage I–III esophageal
cancer receive combination
chemotherapy and recombinant IFN-α
followed by surgery and/or RT
3 (NCT00054561) Completed
(N = 376)
Multicenter
randomized
controlled trial
To compare the combination of
isotretinoin, recombinant IFN-α,a n d
vitamin E with observation only in
patients with stage III or IV HNSCC
Pegylated IFN-α2b 2 (NCT00276523) Completed
(N = 72)
Randomized
controlled trial
Pegylated IFN-α2b at 3 diﬀerent dose
levels is compared with no treatment
prior to resection of stage II–IV HNSCC
IL-2
2 (NCT00006033) Completed
(N = 80)
Multicenter
open-label
To compare IL-2 gene with methotrexate
in the treatment of recurrent or
refractory stage III/IV HNSCC
3 (NCT00002702) Recruiting
(N ∼ 260)
Multicenter
randomized,
controlled trial
To compare surgery and RT with and
without rIL-2 in patients with SCC of the
mouth or oropharynx
IL-12 1/2 (NCT00004070)
Active, not
recruiting
(N ∼ 28–34)
Multicenter
rising-dose study
Patients with unresectable, recurrent, or
refractory HNSCC receive IL-12 gene
twice during week 1 and once weekly
during weeks 2–7
ALT-801 (a
recombinant fusion
p r o t e i nw i t ha nI L - 2
component)
1 (NCT00496860) Recruiting
(N ∼ 46)
Multicenter
dose-escalation study
To determine the MTD of ALT-801 in
previously treated patients with
progressive metastatic malignancies,
including HNC
IRX-2 2 (NCT00210470) Closed
(N = 27)
Multicenter
open-label trial
Study of IRX-2 with cyclophosphamide,
indomethacin, and zinc in patients with
newly diagnosed, resectable stage II–IV
HNSCC. The study is being conducted to
conﬁrm the safety and biological eﬀect of
the IRX-2 regimen in the same
population to be studied in a planned
randomized phase 3 trial. The primary
f o c u sw i l lb eo no b s e r v a t i o n sm a d ef r o m
the start of treatment through the
planned surgical resection of the primary
tumor.
HNC: head and neck cancer; HNSCC: head and neck squamous cell carcinoma; IFN: interferon; IL: interleukin; MTD: maximum tolerated dose; RT:
radiotherapy.
used to block immunosuppression due to the prostaglandins
synthesized by the tumor and by suppressor macrophages,
and zinc is used to reverse cellular immunodeﬁciency [52].
IthasbeenshownthatexvivotreatmentwithIRX-2leads
todose-andtime-dependentapoptosissuppressionofTcells
(P<. 001 to P<. 005). IRX-2 also potentiated antitumor
eﬀects of immune cells, such as upregulation of key signaling
molecules’ expression on dendritic cells to increase their
functions. Local delivery of IRX-2 induced systemic changes
in both peripheral blood memory and naive T cell subsets
[53].
T h er e s u l t so fam u l t i c e n t e rp h a s e2t r i a lo fI R X - 2
have recently been reported. In this trial, 27 previously
untreated, resectable patients with stage II-IV oral cavity
(15), oropharynx (8), larynx (3), or hypopharynx (1)
HNSCC received the IRX-2 regimen prior to surgery. The
regimen consisted of intravenous cyclophosphamide on day
1, followed by bilateral perilymphatic injections of IRX-2
(115 U bilateral daily) from day 4 to 15, and daily oral
indomethacin, zinc, and omeprazole from day 1 to 21. The
IRX regimen was well tolerated, with minimal acute toxicity
(grade <2). Tumor responses (>12% decrease on blinded
CT review) were seen in 16% of patients, and 74% patients
hadeitherreductionorstabletumorsize.Signiﬁcantchanges
in tumor and lymph node lymphocytic inﬁltration were
observed in the IRX-treated patients. Data on estimated 2-
year overall survival (72%) and disease-free survival (67%)
were favorable compared to those reported for 81 concurrent
treatment matched controls [54, 55].
5.2. Targeted Immunotherapy in HNSCC. Technological
advances have allowed researchers to identify several kinds of
tumor-associated antigens that are now under investigation
as therapeutic targets in HNSCC [56]. One category is6 Journal of Oncology
Table 2: Monoclonal antibodies (excluding anti-EGFR agents) in clinical development in head and neck cancer [40].
Agent Phase Status Study Type Description
Bevacizumab
Clinicaltrials.gov search
retrieves records for
3p h a s e1t r i a l s
2p h a s e1 / 2t r i a l s
11 phase 2 trials
1p h a s e3t r i a l
The phase 1, 1/2, and
2t r i a l sa r ec o m p l e t e d
or ongoing
The phase 3 trial is
recruiting
Several
The early-phase trials are exploring
several diﬀerent regimens
The phase 3 trial is a multicenter,
randomized, controlled trial in which
patients with recurrent or metastatic
HNSCC receive chemotherapy ±
bevacizumab.
Chemotherapy consists of cisplatin,
docetaxel, and ﬂuorouracil.
anti-CD45 MAb 1 (NCT00608257) Completed
(N = 18) Dose-escalation study
Patients with EBV-positive
nasopharyngeal cancer receive
autologous EBV-speciﬁc cytotoxic T
cells in combination with anti-CD45
MAb
MN-14
(anti-CEA
MAb)
1/2 (NCT00004048) Active, not recruiting
(N ∼ 30) Dose-escalation study
Patients with medullary thyroid cancer
undergo radioimmunotherapy with
MN-14 alone or combined with
doxorubicin and peripheral blood
stem cell rescue
CEA: carcinoembryonic antigen; EBV: Epstein-Barr virus; HNSCC: head and neck squamous cell carcinoma; MAb: monoclonal antibody.
tumor-speciﬁc antigens (also called germ cell antigens or
cancer testes antigens), which are silenced in normal tissues
but are reactivated in certain tumors [31]. For example, up
to 71% of HNSCCs express antigens from at least 1 of 6
melanoma antigen genes (MAGEs) [57], notably MAGE-
1 and MAGE-3 [58] .A n t i g e nf r o mN Y - E S O - 1 ,ag e n e
expressed in normal ovary and testis, is highly expressed in
av a r i e t yo ft u m o rt y p e s[ 59], including HNSCC [60].
Another category of tumor-associated antigen is tumor-
speciﬁc mutated proteins that are unique to the tumor and
may contribute to the malignant phenotype, for example,
t u m o rs u p p r e s s o rg e n ep 5 3[ 31]. Preclinical work suggests
not only that p53 is mutated in many more cases of HNSCC
than originally thought but also that wild-type p53 is often
associated with highly oncogenic strains of HPV (types 16
and 18) [61].
Antigens overexpressed in tumors are a third category of
targetsunderinvestigation.Notableexamplesarecarcinoem-
bryonic antigen (CEA), HER-2/neu, VEGF, and EGFR [31].
Antigensderivedfromoncogenicviruses,suchastheHPVE6
and E7 oncoproteins, are also important targets in HNSCC
[62–64].
5.2.1. Monoclonal Antibody (MAb) Immunotherapy. Ad-
vancements in technology have allowed identiﬁcation and
large-scale production of monoclonal antibodies, which are
highly speciﬁc to their target, are better tolerated than cyto-
toxic drugs, and can induce tumor cell apoptosis [31]. These
advantages have made MAb immunotherapy a compelling
ﬁeld of research (Table 2)[ 40].
EGFR is overexpressed in more than 90% of HNSCCs
[10],andoverexpressionisoftenassociatedwithpoorclinical
prognosis and outcome, including reduced disease-free and
overall survival. A variety of EGFR inhibitors have been
developed that function either by binding to the extracellular
ligand binding domain of the EGF receptor (e.g., MAbs such
as cetuximab), or by inhibiting the intracellular tyrosine
kinase activity of the receptor [65, 66]. While the exact
mechanisms of action of these inhibitors are unclear, cetux-
imabhasbeenshowntoactivateantibody-dependantcellular
cytotoxicity (ADCC). The in vivo success of cetuximab
in combination with radiation has inspired exploration of
other anti-EGFR agents. These include matuzumab [67],
panitumumab (also called ABX-EGF) [68], ICR62 [69],
nimotuzumab (also called h-R3) [70], MAb 806 [71], and
zalutumumab [66]. Anti-EGFR agents have recently been
reviewed elsewhere [66].
VEGF is highly expressed in most human cancers [72,
73], and in HNSCC its expression may be a signiﬁcant factor
in survival [74]. Therefore, recent studies have combined
the antiangiogenic agent bevacizumab with chemotherapy.
For example, an ongoing phase 2 trial (N = 14) pairs
bevacizumab with pemetrexed in ﬁrst-line treatment of
recurrent and/or metastatic HNSCC; interim results show an
overallresponserateof45%amongthe11evaluablepatients,
but also a high rate of bleeding complications in susceptible
patients [75]. Bevacizumab is also being investigated in head
and neck cancer in combination with erlotinib, a small-
molecular-weight tyrosine kinase inhibitor [76].
There is evidence that VEGF and VEGF receptor-2 are
coexpressed in HNSCC and that coexpression is associated
with a higher proliferation rate and worse survival [74].
Adjuvant therapy with VEGFR-2 inhibitors might disrupt
both the paracrine and autocrine actions of VEGF and be
beneﬁcial in HNSCC patients [77].
An investigational anti-VEGF antibody, 2C3, appears
to control tumor metastasis by a mechanism somewhat
diﬀerent from that of bevacizumab: in a preclinical study of
breast cancer, it inhibited lymphangiogenesis and decreased
intratumoral lymph vessel development [78].Journal of Oncology 7
Table 3: Vaccines in clinical development in head and neck cancer [40].
Agent Phase Status Study Type Description
ALVAC-CEA vaccine 2 (NCT00003125)
Active, not
recruiting
(N ∼ 24)
Partially randomized
pilot study
For patients with CEA-expressing advanced
tumors, including HNC. In stage I, patients
receive vaccinia-CEA vaccine and then
ALVAC-CEA (CEA-avipox) vaccine, or the
reverse sequence. In stage 2, patients receive
whichever vaccine was superior, plus
GM-CSF ± IL-2.
Anti-CEA
RNA-pulsed DC
vaccine
1 (NCT00004604)
Active, not
recruiting
(N ∼ 18)
Dose-escalation study
To determine the MTD of the vaccine in
patients who have refractory metastatic
cancer, including HNC, that expresses CEA
EBV LMP-2 peptide
vaccine
1 (NCT00078494) Completed
(N = 99) Randomized study
Patients with nasopharyngeal cancer that
has been controlled with standard therapy
receive 1 of 2 LMP-2 vaccines to determine
which better prevents cancer recurrence.
LMP-2 is a protein produced by EBV.
HPV-16 E7/E6
peptide vaccine
1 (NCT00019110) Completed
(N = 40–46)
Multicenter
open-label study
Patients with advanced or recurrent cancers,
including HNC, receive a vaccine that
contains the HPV-16 E7 and E6 peptides
JAX-594 (thymidine
kinase-deleted
vaccinia virus plus
GM-CSF)
1 (NCT00625456) Recruiting
(N ∼ 24) Dose-escalation study To ﬁnd the MTD of JAX 594 in patients with
refractory solid tumors, including HNSCC
MAGE-A3/HPV-16
vaccine
1 (NCT00257738) Recruiting
(N ∼ 90) Dose-escalation study
Patients with HNSCC receive a vaccine
comprised of MAGE-A3 and HPV-16
peptides
1 (NCT00704041) Recruiting
(N ∼ 48) Dose-escalation study
To evaluate 4 doses of the
MAGE-A3/HPV-16 vaccine in 2 cohorts of
HNSCC patients those with
MAGE-A3-positive tumors and those with
HPV-16-positive tumors
Multiple-peptide
vaccine (LY6K,
VEGFR1, VEGFR2)
1 (NCT00561275) Completed
(N = 6) Open-label trial
Patients with esophageal cancer receive a
vaccine containing multiple peptides and
GM-CSF
p53-pulsed DC
vaccine
1 (NCT00404339) Recruiting
(N ∼ 50)
Randomized safety
trial
Patients with HNSCC receive autologous
DCs loaded with wild-type p53 peptides, ±
T-helper peptide epitope
Ras peptide vaccine 2 (NCT00019331) Completed
(N = 60) Single-center trial
To compare 3 regimens of vaccine therapy
with tumor-speciﬁc mutated Ras peptides
plus IL-2 or GM-CSF in patients with
metastatic solid tumors, including HNC,
that potentially express mutant Ras.
Fowlpox-CEA-
TRICOM vaccine
(fCEA-TRI)
1 (NCT00028496) Completed
(N = 48) Dose-escalation study
To evaluate fCEA-TRI ± GM-CSF in
patients with advanced or metastatic cancer,
including HNC.
1 (NCT00021424) Completed
(N = 20) Dose-escalation study
To ﬁnd the MTD of fCEA-TRI in patients
with advanced SCC of the oral cavity or
oropharynx or nodal or dermal metastases
1 (NCT00027534) Completed
(N = 6–18) Dose-escalation study
Immunotherapy comprises autologous DCs
treated with fCEA-TRI in patients with
CEA-expressing advanced or metastatic
cancer, including HNC.
CEA: carcinoembryonic antigen; DC: dendritic cell; EBV: Epstein-Barr virus; HNC: head and neck cancer; HNSCC: head and neck squamous cell carcinoma;
IL: interleukin; GM-CSF: granulocyte macrophage colony-stimulating factor; HPV: human papillomavirus; LY6K: lymphocyte antigen 6 complex, locusK ;
MAGE: melanoma antigene gene; MTD: maximum tolerated dose; TRICOM: TRIad of COstimulatory Molecules (aimed at stimulating a cytotoxic T-cell
response); VEGFR: vascular endothelial growth factor receptor.8 Journal of Oncology
Another new treatment strategy is to target CEA, an
antigen present on the surface of a majority of HNSCC
tumors[31,79],viaMAbimmunotherapyplusradiotherapy.
A phase 1 trial combined high-dose labetuzumab, a 90Y-
labeled humanized anti-CEA MAb, with doxorubicin and
peripheral blood stem cell rescue for patients with advanced
thyroid cancer. Objective responses were rare, but the ther-
apy was well tolerated and there was evidence of antitumor
activity [80]. Another study in advanced thyroid cancer
evaluated bispeciﬁc MAb (BsMAb), which targets both
CEA and diethylenetriamine penta-acetic acid. Combination
therapy with BsMAB and a 131I-labeled bivalent hapten
was associated with a median survival time of 110 months,
signiﬁcantly longer than the 61 months seen in untreated
patients (P<. 03) [81].
5.2.2. Cancer Vaccines. Two common types of therapeutic
cancer vaccines are peptide/protein-based or dendritic cell-
based. To produce the ﬁrst type, an adjuvant is combined
with 1 or more peptides/proteins commonly expressed on
HNSCC such as p53, MAGE, or HPV. It is expected that
the immune system, in response to the adjuvant, will also
respond to tumor cells that express the antigen(s). For the
secondtype,dendriticcellsareremovedfromcancerpatients
through leucopheresis and stimulated with an appropriate
tumor antigen, then reinjected so that they will activate T
cells speciﬁc to the patient’s tumor. The strategies can be
combined, as when dendritic cells are pulsed with mutant
p53 peptides [82, 83]. A phase 1 trial of this approach is
under way [40]. Dendritic cells can also be pulsed with
MAGEpeptides.Inonerecentstudy,avaccinethatcombines
MAGE-1 and MAGE-3 peptides was administered following
surgery and chemotherapy for 2 patients with primary
malignant melanoma of the esophagus, which has an
extremely poor prognosis. One patient had stable disease for
5 months and survived for 12; the second was without tumor
recurrence for 16 months after treatment, and, following
esophagectomy, had survived for 49 months at the time of
trial report publication [84]. In a phase 1/2 study, an MAGE-
3 peptide + ASO2B adjuvant vaccine produced clinical
responses in 6 of 12 patients with metastatic tumors (mainly
melanoma), but the response could not be clearly correlated
with cytokine proﬁle, levels of anti-MAGE-3 antibody, or
IgG subclass [85]. A phase 2 pilot study has recently been
completed that made use of vaccines constructed of HPV 16
peptides E6 and E7 alone or in combination with MAGE-
3p e p t i d e s[ 40]. A common issue challenging the further
development of clinically useful vaccines is the need to
develop new and more eﬀective vaccine adjuvants.
Cancer vaccines for HNSCC can also be based on DNA
or RNA. The nucleic acid containing the gene for the antigen
is manipulated exogenously so it will be taken up, expressed,
and processed by antigen-presenting cells, in the hope that
the immune system will target tumor cells containing the
same antigen. Vaccines of this type have shown potential
for targeting CEA when recombinant fowlpox or ALVAC
(canarypox) viruses, which do not replicate in human cells,
are used as vectors, with and without GM-CSF [86, 87].
Nucleotide-based vaccines targeting HPV are also being
studied in HNSCC. Research in China showed that in a
mouse model of esophageal SCC, a fusion protein vaccine
combining the HPV-16 oncoproteins E6 and E7 signiﬁcantly
inhibited tumor growth and size (P<. 01), and 25% of
vaccinated animals remained tumor-free at 2 days [88]. In
another study, Chen et al. constructeda vaccine which linked
Mycobacterium tuberculosis heat-shock protein 70 to HPV-
16 E7; the E7-speciﬁc T-cell response to murine tumors that
expressed HPV-16 E7 was at least 30-fold higher with the
fusion vaccine than with a vaccine based on unmodiﬁed E7
[59]. A list of cancer vaccines in clinical trials for treatment
of head and neck cancer is provided in Table 3 [40].
6. Conclusions
Given the well-established role of immune system dysfunc-
tion in HNSCC, immunotherapy is an attractive treatment
option, potentially associated with more tolerable side
eﬀe c t sa n di m p r o v e de ﬃcacy. Recent advances in identifying
HNSCC tumor antigens have provided targets for mono-
clonal antibodies and other modes of immunotherapy. In
particular, advances in the understanding of cell-mediated
immunity have led to several promising approaches to
HNSCC treatment that involve systemic cell-mediated
immunotherapy, such as the delivery of cytokines that can
stimulate a durable immune response and tumor rejection.
These novel treatment modalities, either as monotherapy or
combined with other forms (e.g., MAb therapy), represent
future directions in the treatment of HNSCC.
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